Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy-Reference-Cited by-同舟云学术

Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy

Published:2018-07 Issue:27 Volume:97 Page:e11307
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Gaeta Giovanni Battista,Aghemo Alessio,Menzaghi Barbara,D’Offizi Gianpiero,Giorgini Alessia,Hasson Hamid,Brancaccio Giuseppina,Palma Maria,Termini Roberta

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference11 articles.

1. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study;Lawitz;Lancet,2014

2. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study;Kwo;Hepatology,2016

3. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2);Lawitz;Hepatology,2016

4. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection;Sulkowski;Gastroenterology,2016

5. Real-world effectiveness of simeprevir-containing regimens among patients with chronic hepatitis C virus: the SONET study;Alam;Open Forum Infect Dis,2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil;Clinics and Research in Hepatology and Gastroenterology;2020-06

2. Ribavirin/simeprevir/sofosbuvir;Reactions Weekly;2018-08